Chronic Heart Failure: Expanding the Toolbox of Therapeutic Options

A series of CME-certified Programs

Presentation Slides

Click here to view a PDF of the presentation slides for this series.

Program Description

Heart failure (HF), a leading cause of mortality and morbidity, occurs when the heart is unable to pump sufficiently to maintain blood flow to meet the needs of the body. Although the treatment for HF has seen remarkable progress, there is still a need to develop new therapies to improve long-term survival. This has driven the pursuit for novel HF drugs with superior efficacy and safety. These efforts have led to the recent FDA approval of two new agents for treatment of HF, with additional candidates in late-stage development.

Chronic Heart Failure: Expanding the Toolbox of Therapeutic Options will review these developments and help healthcare providers understand the clinical properties of traditional and newly approved heart failure drugs. It will also help clinicians incorporate evidence-based guidelines and results from large outcomes studies into their clinical practices and choose the therapies best suited to improve the clinical outcomes of their HF patients.

Target Audience

This program is intended for community cardiologists, interventional cardiologists, internal medicine physicians, and other health care professionals who manage HF patients.

Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Identify the epidemiology and major drivers of heart failure
  • Select evidence-based therapies that have been shown to reduce morbidity and mortality in patients with HFrEF and pursue best clinical practices to treat HFpEF
  • Examine the diverse mechanisms of action of established and newly approved treatment options, and the evidence supporting their use
Accreditation Statements

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statements

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For information about the accreditation of this program, please email

Live Program Calendar:

Back to Top


  1. Welcome and Introduction
  2. Heart Failure: Cardiac Pump Insufficient to Meet Metabolic Needs
  3. Heart Failure: Reduced Ejection Fraction (HFrEF) and Preserved Ejection Fraction (HFpEF)
  4. History and Evolution of HF Treatment Options
  5. Q&A Session and Concluding Remarks

Steering Committee


Director, Heart Failure Section
Heart and Vascular Center
The MetroHealth System
Professor of Medicine, Physiology, and Biophysics
Case Western Reserve University
Cleveland, OH

Mark E. Dunlap, MD is Professor of Medicine, Physiology, and Biophysics at Case Western Reserve University in Cleveland, OH. He received his medical doctorate from the University of Tennessee College of Medicine in Memphis, TN, and completed his medicine, cardiology, and research training at the Medical College of Virginia. He currently serves as Director of the Heart Failure Section for the MetroHealth System in Cleveland, OH.

His research has focused on abnormalities of autonomic control in hypertension and heart failure, showing that cardiopulmonary baro-reflex control of sympathetic activity is blunted in both animals and humans with HF. He has also focused on mechanisms underlying abnormal cholinergic control in HF, including the role of nicotinic acytylcholine receptor subtypes in ganglionic transmission. More recently his work has focused on the role of sympathetic activation in causing redistribution of fluid from splanchnic venous vessels into the circulatory volume leading to decompensated HF.

Dr. Dunlap has been a part of numerous clinical trials designed to test therapies aimed at treating the neurohumoral excitatory state in HF, including DIG (digoxin), MERIT-HF (beta-blocker), CHARM (angiotensin receptor inhibitor), OVERTURE (neutral endopeptidase inhibitor), PROTECT (adenosine a1 inhibitor), BALANCE (vasopressin receptor inhibitor), TOPCAT (aldosterone receptor blocker), and ASCEND (nesiritide), and has served on the Steering Committees and Endpoint Committees for several clinical trials. He also served as PI for the Symplicity HTN-1 and HTN-3 trials of renal denervation for the treatment of resistant hypertension, and is currently an investigator in the NHLBI-sponsored National HF Research Network. He has served on numerous study sections for the NHLBI, the American Heart Association, and the Department of Veterans Affairs, and is past President of the Society for Heart Brain Medicine.


Chief, Division of Cardiology
Tufts Medical Center
Professor of Medicine and Radiology
Tufts University School of Medicine
Boston, MA

James E. Udelson, MD is Chief of the Division of Cardiology, as well as Director of Nuclear Cardiology, at Tufts Medical Center. He is a Professor of Medicine and Radiology at Tufts University School of Medicine in Boston, and received the Distinguished Faculty Award from the Medical School in 2012. Dr. Udelson’s research interests involve studying the effects of new therapeutic modalities in the setting of heart failure and chronic coronary artery disease, as well as studying the development of imaging modalities to assess those effects. He has been an Associate Editor of the journal Circulation since 2004, and, in 2008, was appointed as the initial Editor-in-Chief for the journal Circulation: Heart Failure. He is on the editorial board and has served as a Guest-Editor for the Journal of the American College of Cardiology and the Journal of Nuclear Cardiology.

Dr. Udelson has served on the AHA/ACC/ASNC Radionuclide Imaging Guidelines Writing Task Force, as well as numerous other national Guideline and Appropriate Use Criteria writing groups, including as a Co-chair of the ACC/ACR Writing Committee for Appropriate Use Criteria to Assess Imaging Modalities to Evaluate Chest Pain in the Emergency Department. He is a chapter author for Braunwald’s Heart Disease textbook for several editions.

Dr. Udelson is Past President of the American Society of Nuclear Cardiology, and has served a 5-year term on the Board of Trustees of the American College of Cardiology (ACC). He has chaired the ACC’s Cardiovascular Imaging Committee, served on the ACC Publications Committee, and completed a term as Chair of the ACC Governance Committee. He has recently commenced a term as a member of the Executive Council of the Heart Failure Society of America.

Back to Top
Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be emailed 2 weeks after submission of a completed evaluation form.

There is no fee associated with this program.

Special Services

Event staff will be glad to assist you with any special needs. Please email at least 5 days prior to the program.

Back to Top

Jointly provided by Potomac Center for Medical Education and Rockpointe

Supported by an independent educational grant provided by Novartis Pharmaceutical Corporation.

©2016 Rockpointe